Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

A randomised clinical trial found that pressure-mediated biofeedback improves postpartum stress urinary incontinence.

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that ...

After a comprehensive two-year follow-up, researchers found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Overtreatment of prostate cancer among men with limited life expectancy is increasing in the United States. Two-thirds of men ...

Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

While it is clear that urinary incontinence in the elderly is a prevalent, bothersome and costly problem, it is often dismissed as a normal part of aging by patients, caregivers and physicians.

Prostate cancer is a common cancer in men in many countries, including the UK. While exercise is beneficial for patients, ...

The projected global photoacoustic microscopy market opportunity is likely to hit the USD 120 billion valuation mark by 2024.